Article
Surgery
Pascale Mariani, Francois-Clement Bidard, Aurore Rampanou, Alexandre Houy, Vincent Servois, Toulsie Ramtohul, Gaelle Pierron, Marion Chevrier, Benjamin Renouf, Olivier Lantz, Sophie Gardrat, Anne Vincent-Salomon, Sergio Roman-Roman, Manuel Rodrigues, Sophie Piperno-Neumann, Nathalie Cassoux, Marc-Henri Stern, Shufang Renault
Summary: This study reports the detection rate and prognostic impact of circulating tumor DNA in patients undergoing surgical resection of liver metastases in uveal melanoma. If confirmed by further studies, this noninvasive biomarker could inform treatment decisions for liver metastases in uveal melanoma patients.
Article
Medicine, General & Internal
Matthias Schneider, Niklas Schaefer, Christian Bode, Valeri Borger, Lars Eichhorn, Frank A. Giordano, Erdem Gueresir, Muriel Heimann, Yon-Dschun Ko, Felix Lehmann, Anna-Laura Potthoff, Alexander Radbruch, Christina Schaub, Katjana S. Schwab, Johannes Weller, Hartmut Vatter, Ulrich Herrlinger, Jennifer Landsberg, Patrick Schuss
Summary: Studying preoperative laboratory inflammation markers in melanoma patients with brain metastasis undergoing surgery revealed that elevated CRP levels, higher NLR and PLR, and lower LMR were associated with reduced overall survival rates. These markers could potentially be integrated into preoperative treatment planning for affected patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Amanda Nijhuis, David Chung, Kevin London, Roger Uren, John Thompson, Omgo Nieweg
Summary: This study assessed the value of ultrasound examination in detecting additional ITMs in melanoma patients, revealing that ultrasound was able to identify extra lesions in over half of the patients and influenced management in one-third of cases.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Pauline Roussille, Marie Auvray, Damien Vansteene, Thierry Lecomte, Eugenie Rigault, Marianne Maillet, Christophe Locher, Marie Dior, Vincent Hautefeuille, Pascal Artru, May Mabro, Yann Touchefeu, Lysiane Marthey, Valerie Moulin, Samy Louafi, Cedric Lecaille, Romain Chautard, Astrid Lievre, Aziz Zaanan, Jaafar Bennouna, Antoine Berger, Sheik Emambux, Violaine Randrian, David Tougeron
Summary: This study evaluated prognostic factors of brain metastases from colorectal cancer and found that ECOG performance status, number of brain metastases, and number of chemotherapy lines are the most relevant factors in the management of patients with this condition.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Yang Wang, Bin Lian, Lu Si, ZhiHong Chi, XiNan Sheng, Xuan Wang, LiLi Mao, BiXia Tang, SiMing Li, XieQiao Yan, Xue Bai, Li Zhou, ChuanLiang Cui, Jun Guo
Summary: The study identified the clinicopathological characteristics and prognostic factors of patients with melanoma brain metastases (MBM) in the East Asian population, highlighting mucosal subtype as an adverse prognostic factor. For BRAF mutation patients with MBM, first-line BRAF/MEK inhibitor therapy may provide potential survival benefits compared to first-line anti-PD-1 therapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Surgery
Tianhao Li, Haoren Jing, Yongdan Zhang, Zegang Cao, Lizhong Zhao, Xipeng Zhang, Tianwei Sun, Mingqing Zhang
Summary: This study found that the prognosis of BM patients with left-sided colon cancer and right-sided colon cancer are different, and N staging and primary tumor sidedness are independent prognostic factors for CRC with BM.
UPDATES IN SURGERY
(2023)
Article
Oncology
Dimitri G. Trembath, Eric S. Davis, Shanti Rao, Evan Bradler, Angelica F. Saada, Bentley R. Midkiff, Anna C. Snavely, Matthew G. Ewend, Frances A. Collichio, Carrie B. Lee, Georgia-Sofia Karachaliou, Fatih Ayvali, David W. Ollila, Michal T. Krauze, John M. Kirkwood, Benjamin G. Vincent, Nana Nikolaishvilli-Feinberg, Stergios J. Moschos
Summary: The presence of high tumor-infiltrating lymphocytes (TILs) in patients undergoing craniotomy for melanoma brain metastases (MBM) before 2011 may have prognostic significance. Intratumoral hemorrhage is associated with tumor volume, high expression of basic fibroblast growth factor (bFGF), and high density of CD31+alpha SMA- blood vessels.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Shizhao Cheng, Lei Yang, Xin Dai, Jing Wang, Xingpeng Han
Summary: The incidence of brain metastases in esophageal cancer patients is rare, with a prognosis of only 5 months. Both bone and lung metastases are significant factors for the development and prognosis of brain metastases. Various clinical characteristics, such as age, race, tumor location, histology subtype, and metastases sites, are associated with the occurrence of brain metastases in esophageal cancer patients. The nomogram is a reliable tool for predicting brain metastases.
Article
Oncology
Enfang Shan, Yi-nan Cao, Yang Zhang, Wen Chen, Xurui Ren, Shanjie Zhu, Xueru Xi, Shuai Mu, Mian Ma, Tongle Zhi, Xianwen Li
Summary: This study investigates the role of CACNG3 in the progression and survival outcome of gliomas and identifies it as a potential new molecular target for diagnosis and treatment. CACNG3 expression is negatively associated with glioma grades and is significantly reduced in certain molecular subtypes. Functional analysis suggests that CACNG3 may affect glioma development through interference with synaptic transmission. In addition, the commonly used glioma treatment, temozolomide, increases CACNG3 expression. Overall, CACNG3 plays a vital role in glioma occurrence and development and could serve as a biomarker for targeted therapy.
Article
Oncology
Zenan Lin, Daniela Susskind
Summary: This study suggests that serum BAFF levels may serve as a potential marker for detecting UM metastases, as patients with metastases showed significantly higher levels of BAFF and a correlation with metastatic burden was observed. Positive BAFF staining was also found in UM tissue specimens, indicating a possible role of the BAFF signaling pathway in UM progression.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Ophthalmology
Gaurav Garg, Paul T. Finger, Tero T. Kivela, E. Rand Simpson, Brenda L. Gallie, Svetlana Saakyan, Anush G. Amiryan, Vladimir Valskiy, Kimberly J. Chin, Ekaterina Semenova, Stefan Seregard, Maria Fili, Matthew Wilson, Barrett Haik, Josep Maria Caminal, Jaume Catala-Mora, Cristina Gutierrez, David E. Pelayes, Anibal Martin Folgar, Martine Johanna Jager, Mehmet Dogrusoz, Gregorius P. M. Luyten, Arun D. Singh, Shigenobu Suzuki
Summary: The study analyzed ocular and systemic findings of patients with systemic metastasis, finding a certain proportion of uveal melanoma patients presented with metastasis, mostly originating in the choroid. Even small T1 tumors were found to be stage IV at initial presentation.
BRITISH JOURNAL OF OPHTHALMOLOGY
(2022)
Article
Oncology
TengFei Deng, Chaoyong Wang, Cong Gao, Qiang Zhang, Jun Guo
Summary: This study explores the correlation between ITGAL expression, immune infiltration, clinical prognosis, and specific types of T cells in melanoma tissue. The findings suggest that ITGAL plays a crucial role in melanoma and has the potential to regulate tumor immune infiltrating cells. It may serve as a diagnostic biomarker and therapeutic target for advanced melanoma.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Michael S. Sander, Igor Stukalin, Isabelle A. Vallerand, Siddhartha Goutam, Benjamin W. Ewanchuk, Daniel E. Meyers, Aliyah Pabani, Don G. Morris, Daniel Y. C. Heng, Tina Cheng
Summary: This study utilized a modified immune prognostic index (IPI) to stratify MUM patients and found significant differences between favorable and poor IPI groups in overall survival (OS), time to treatment failure (TTF), and immune-related adverse events (irAEs). Therefore, the IPI may be a useful tool in clinical practice for identifying MUM patients who are more likely to experience irAEs and realize a survival benefit from ICI treatment.
Article
Oncology
L. Susok, M. Stucker, F. G. Bechara, E. Stockfleth, T. Gambichler
Summary: When compared to SSM patients, NM patients are more likely to have higher Clark levels, thicker tumors, less tumor regression, more frequently ulcerated tumors, and less likely precursor lesions such as nevi. NM patients have significantly higher rates of disease relapse and death within a 5-year follow-up. On multivariate analysis, tumor thickness and positive SLNB predict disease relapse in NM patients, while male sex and tumor thickness predict melanoma-specific death in NM patients. Histologic regression also remains a significant independent negative predictor of NM death.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Domenico Mallardo, Ester Simeone, Lucia Festino, Marilena Tuffanelli, Vito Vanella, Claudia Trojaniello, Maria Grazia Vitale, Margaret Ottaviano, Mariaelena Capone, Gabriele Madonna, Francesca Sparano, Eleonora Cioli, Luigi Scarpato, Marco Palla, Rossella Di Trolio, Paolo Meinardi, Corrado Caraco, Gerardo Ferrara, Paolo Muto, Ernesta Cavalcanti, Paolo Antonio Ascierto
Summary: This study investigated the prognostic significance of IL-6 serum levels before and during cemiplimab immunotherapy in patients with advanced cutaneous squamous cell carcinoma. The results showed that high IL-6 levels were associated with poorer survival and shorter progression-free survival. Additionally, patients whose IL-6 levels increased after treatment had a worse response to immunotherapy compared to those with reduced or stable levels.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Letter
Dermatology
Mark B. Faries, Alistair J. Cochran, John F. Thompson
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2023)
Article
Oncology
L. H. J. Holtkamp, S. Lo, M. Drummond, J. F. Thompson, O. E. Nieweg, A. M. Hong
Summary: This study compares the oncological outcomes of hypofractionated and conventionally fractionated adjuvant radiotherapy in high-risk stage III melanoma patients. The results show that overall survival, recurrence-free survival, and lymph node field control rates were similar between the two methods before effective systemic immunotherapy became available. Extranodal spread and an increasing number of positive lymph nodes were associated with unfavorable outcomes.
Article
Oncology
Andrew W. Hahn, Ashley Menk, Dayana B. Rivadeneira, Ryan C. Augustin, Mingchu Xu, Jun Li, Xiaogang Wu, Aditya K. Mishra, Tuba N. Gide, Camelia Quek, Yan Zang, Christine N. Spencer, Alexander M. Menzies, Carrie R. Daniel, Courtney W. Hudgens, Theodore Nowicki, Lauren E. Haydu, M. A. Wadud Khan, Vancheswaran Gopalakrishnan, Elizabeth M. Burton, Jared Malke, Julie M. Simon, Chantale Bernatchez, Nagireddy Putluri, Scott E. Woodman, Y. N. Vashisht Gopal, Renato Guerrieri, Grant M. Fischer, Jian Wang, Khalida M. Wani, John F. Thompson, Jeffrey E. Lee, Patrick Hwu, Nadim Ajami, Jeffrey E. Gershenwald, Georgina Long, Richard A. Scolyer, Michael T. Tetzlaff, Alexander J. Lazar, Dirk Schadendorf, Jennifer A. Wargo, John M. Kirkwood, Ralph J. DeBerardinis, Han Liang, Andrew Futreal, Jianhua Zhang, James S. Wilmott, Weiyi Peng, Michael A. Davies, Greg M. Delgoffe, Yana G. Najjar, Jennifer L. McQuade
Summary: This study investigated the association between body mass index (BMI) and tumor or microbiome characteristics in patients with metastatic melanoma. The findings suggest that the host metabolic phenotype influences melanoma metabolism and may explain the improved outcomes observed in overweight/obese patients treated with immune checkpoint inhibitors and targeted therapies.
CLINICAL CANCER RESEARCH
(2023)
Review
Dermatology
Alexander H. R. Varey, Gabrielle J. Williams, Serigne N. Lo, Cecilia Y. Taing, Andrea Maurichi, Mario Santinami, Richard A. Scolyer, John F. Thompson
Summary: This review evaluated the management and prognostic utility of excision margins and sentinel node biopsy (SNB) for patients with melanocytic tumors of uncertain or low malignant potential. The findings indicate a lack of clear guidance on optimal excision margins and the limited prognostic value of SNB for this tumor type. Therefore, routine SNB should not be offered for these tumors.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Article
Pathology
R. V. Rawson, I. A. Vergara, J. R. Stretch, R. P. M. Saw, J. F. Thompson, S. N. LO, R. A. Scolyer, K. J. Busam
Summary: Desmoplastic melanoma (DM) is a rare subtype of melanoma with distinct features. Studies have shown that pure desmoplastic melanoma (PDM) has a lower sentinel lymph node biopsy (SLNB)-positivity rate compared to mixed desmoplastic melanoma (MDM) and non-DM. Therefore, SLNB may not be necessary in PDM patients.
Editorial Material
Oncology
Trine Schoenfeldt, Annette H. Chakera, Omgo E. Nieweg, John F. Thompson
ANNALS OF SURGICAL ONCOLOGY
(2023)
Letter
Oncology
John F. Thompson, John Hyngstrom, Corrado Caraco, Jonathan S. Zager, Tiina Jahkola, Tawnya L. Bowles, Elisabetta Pennacchioli, Harald J. Hoekstra, Marc Moncrieff, Christian Ingvar, Alexander van Akkooi, Michael S. Sabel, Edward A. Levine, Michael Henderson, Reinhard Dummer, Carlo Riccardo Rossi, John M. Kane, Steven Trocha, Frances Wright, David R. Byrd, Maurice Matter, Alastair MacKenzie-Ross, Mark C. Kelley, Patrick Terheyden, Tara L. Huston, Jeffrey D. Wayne, Heather Neuman, B. Mark Smithers, Darius Desai, Jeffrey E. Gershenwald, Shlomo Schneebaum, Anja Gesierich, Lisa K. Jacobs, James M. Lewis, Cristina O'Donoghue, Armando Sardi, J. Greg McKinnon, Craig L. Slingluff, Jeffrey M. Farma, Erwin Schultz, Randall P. Scheri, Sergi Vidal-Sicart, Alessandro A. E. Testori, Richard A. Scolyer, David E. Elashoff, Alistair J. Cochran, Mark B. Faries
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Dermatology
Stephanie C. Blake, Pascale Guitera, Anne E. Cust, Claire Galea, Serigne N. Lo, Richard A. Scolyer, Bruce K. Armstrong, John F. Thompson, Scott W. Menzies, Christine Madronio, Rachael L. Morton, Graham J. Mann, Caroline G. Watts
AUSTRALASIAN JOURNAL OF DERMATOLOGY
(2023)
Letter
Dermatology
Yuan Ni, Caroline G. Watts, Richard A. Scolyer, Christine Madronio, Bruce K. Armstrong, Rachael L. Morton, Scott W. Menzies, Graham J. Mann, John F. Thompson, Serigne N. Lo, Anne E. Cust
Summary: This cross-sectional survey identified risk factors for developing a second primary melanoma. Patients with melanoma who had characteristics such as male sex, older age, high naevus count, or melanoma on the trunk or upper limbs had a substantially higher risk of subsequent melanoma and should therefore be more intensively monitored.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Editorial Material
Oncology
Jeffrey E. Gershenwald
Summary: The prognostic significance of primary cutaneous melanoma tumor mitotic rate (TMR) has been of interest in the clinical field worldwide for many years. Is there a way to utilize the findings from Patuzzo et al. and other studies to enhance the classification and staging of melanoma, as well as develop clinical tools that incorporate TMR for improved risk and prognostic assessment?
Article
Oncology
Alexander H. R. Varey, John F. Thompson, Julie R. Howle, Serigne N. Lo, Sydney Ch'ng, Matteo S. Carlino
Summary: Sentinel node biopsy (SNB) is considered a requirement for pathological staging of melanomas > 1 mm thick, but some argue that it may no longer be necessary for patients with T3 and T4 primary melanomas. However, the prognostic value and therapeutic benefit of knowing a patient's nodal status should not be overlooked.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Andrew T. Li, Jenaleen Law, Sydney Ch'ng, Richard A. Scolyer, John F. Thompson, Serigne N. Lo, Alexander H. R. Varey
Summary: This study provides external validation of the EORTC-DeCOG nomograms for predicting prognosis in melanoma patients. The nomograms perform well in predicting recurrence and distant metastasis, but show poorer performance in predicting overall mortality.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Iris Bartula, Anh D. Tran, Anna K. Nowak, Tasnia Ahmed, Rachael L. Morton, Bryan H. Burmeister, Kari Dolven-Jacobsen, Jenny Nobes, John F. Thompson, Gerald B. Fogarty, Serigne N. Lo, Angela M. Hong
Summary: This study examines the quality of life trajectories of patients with advanced melanoma after local management of brain metastases for 12 months. The results indicate that patients aged 65 years and older, females, those with 2-3 brain metastases, non-surgical treatment, or adjuvant whole brain radiotherapy experience poorer quality of life outcomes in the first 12 months after diagnosis of melanoma brain metastases.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Review
Oncology
Yu Jin Jeong, John F. Thompson, Sydney Ch'ng
Summary: Mucosal melanoma of the head and neck (MMHN) is a rare and aggressive malignancy with poor prognosis. Current understanding of MMHN's epidemiology, staging, and management has been expanded through recent studies. Tumor resection with clear histological margins remains the mainstay of treatment, while alternative staging models and combination therapies show promise. Ongoing clinical trials and further research are needed to fully understand and optimize management of this aggressive disease.
CHINESE CLINICAL ONCOLOGY
(2023)